Brussels, Belgium

Michael Deligny


 

 

Average Co-Inventor Count = 17.1

ph-index = 3

Forward Citations = 25(Granted Patents)


Company Filing History:


Years Active: 2018-2024

Loading Chart...
Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Michael Deligny: Innovator in Pharmaceutical Chemistry

Introduction

Michael Deligny is a notable inventor based in Brussels, Belgium. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative work on fused pentacyclic imidazole derivatives. With a total of 6 patents, Deligny has focused on developing compounds that have the potential to treat a variety of human ailments.

Latest Patents

Deligny's latest patents revolve around a series of fused pentacyclic imidazole derivatives. These compounds are recognized as potent modulators of human TNFa activity, which is crucial in the treatment and prevention of various conditions. These include autoimmune and inflammatory disorders, neurological and neurodegenerative disorders, pain and nociceptive disorders, cardiovascular disorders, metabolic disorders, ocular disorders, and oncological disorders. Specifically, his inventions include 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and their analogs.

Career Highlights

Throughout his career, Michael Deligny has worked with prominent companies in the pharmaceutical industry, including UCB Biopharma Sprl and UCB Biopharma Srl. His work has been instrumental in advancing the understanding and treatment of complex medical conditions.

Collaborations

Deligny has collaborated with various professionals in his field, including Jag Paul Heer and Mark Daniel Calmiano. These collaborations have further enriched his research and development efforts.

Conclusion

Michael Deligny stands out as an influential inventor in the realm of pharmaceutical innovations. His work on fused pentacyclic imidazole derivatives showcases his commitment to addressing significant health challenges through scientific advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…